Post-IPO Share Option Schemes: HKEX Restrictions on Grant Conditions

The Hong Kong Exchange (HKEX) has intensified its scrutiny of post-IPO share option schemes (SOS) over the past 18 months, specifically targeting the grant conditions that listed issuers impose on their employees and directors. This regulatory shift, driven by a series of enforcement actions from the Securities and Futures Commission (SFC) and Listing Division amendments to the Listing Rules in 2024, has created a distinct compliance burden for China concept stocks (中概股) seeking dual listings or secondary listings in Hong Kong. The core issue revolves around the restriction on granting options at a discount to the prevailing market price, a practice historically common in the PRC domestic A-share market but now explicitly curtailed under HKEX Chapter 17 of the Main Board Listing Rules. For cross-border issuers using Variable Interest Entity (VIE) structures, the challenge is compounded by the need to reconcile PRC State Administration of Foreign Exchange (SAFE) circulars with HKEX’s strict pricing and vesting conditions. This article examines the specific restrictions, the mechanics of compliance for VIE-architected issuers, and the practical implications for CFOs and company secretaries drafting post-IPO equity incentive plans.

The Regulatory Foundation: HKEX Chapter 17 and the 2024 Amendments

HKEX Listing Rule Chapter 17 governs share schemes for listed issuers, and the 2024 amendments introduced two critical restrictions on grant conditions that directly affect post-IPO schemes. First, Rule 17.03(4) now mandates that the exercise price of any option granted under a share option scheme must not be less than the higher of: (a) the closing price of the shares on the date of grant; and (b) the average closing price of the shares for the five trading days immediately preceding the date of grant. This eliminates the previous flexibility for issuers to grant options at a discount, even with shareholder approval. Second, Rule 17.03(6) restricts the grant of options to any connected person (as defined under Chapter 14A) unless independent shareholders have approved both the scheme and the specific grant. For China concept stocks with founder-led boards and VIE structures, this connected-person restriction is particularly onerous, as many senior executives hold shares through BVI or Cayman Islands holding entities that trigger connected transaction classification.

The SFC’s 2025 enforcement report highlighted three cases where HKEX issued warning letters to issuers for granting options at a discount to the five-day average, resulting in retrospective adjustments to the exercise price. In one case, a Main Board-listed PRC technology company with a Cayman Islands parent had granted options to its PRC subsidiary employees at a 15% discount to the prevailing market price, relying on a shareholder resolution passed in 2023. The Listing Division required the company to repurchase the options at cost, citing Rule 17.03(4) as having retrospective effect from 1 January 2024 for all new grants. The total financial impact was estimated at HKD 12.8 million in repurchase costs and legal fees, based on the company’s 2024 annual report filing.

VIE Structure Complications: Granting Options to PRC Employees

For issuers operating through VIE structures, the grant of share options to employees of the PRC operating entity faces a dual regulatory hurdle: HKEX’s pricing restrictions under Chapter 17 and PRC foreign exchange controls under SAFE Circular 37 (2014). The VIE structure typically involves a Cayman Islands or BVI-listed parent company granting options to employees of a PRC wholly foreign-owned enterprise (WFOE), which then passes the economic benefit through contractual arrangements to the VIE. Under SAFE Circular 37, PRC-resident employees who receive options in an offshore listed entity must register with the local SAFE branch within 30 days of grant. Failure to register can result in penalties of up to 5% of the option value and restrictions on future capital repatriation.

The interaction with HKEX Rule 17.03(4) creates a timing risk: the exercise price must be fixed at grant, but SAFE registration can take 60-90 business days, during which the market price may fluctuate. If the grant date is set as the date of the board resolution approving the scheme, and the market price subsequently drops below the exercise price, the options become underwater, reducing their incentive effect. A 2025 study by the Hong Kong Institute of Chartered Secretaries (HKICS) found that 68% of VIE-structure issuers surveyed had experienced at least one instance where the gap between the grant date price and the five-day average exceeded 10% during the SAFE registration period, requiring a supplementary board resolution to adjust the grant date.

Performance Conditions and Vesting Schedules Under HKEX Scrutiny

HKEX has also tightened its review of performance conditions attached to post-IPO share options, particularly for issuers with complex VIE structures where the performance metrics may not be directly tied to the listed entity’s financial statements. Rule 17.03(8) requires that performance targets must be “clear, objective, and measurable,” and the Listing Division has issued guidance in 2025 stating that targets based solely on PRC GAAP metrics, without reconciliation to HKFRS or IFRS, will not be accepted. This is a direct response to the prevalence of dual reporting standards among China concept stocks, where the VIE’s PRC GAAP financials often differ materially from the consolidated HKFRS figures due to consolidation adjustments for the VIE contractual arrangements.

A 2024 enforcement action against a GEM-listed PRC healthcare company illustrates the issue. The company had granted options to its VIE employees with a performance condition tied to “revenue growth of the PRC operating entity as reported under PRC GAAP.” The Listing Division determined that this condition was not “clear and measurable” because the PRC GAAP revenue figure was not audited at the listed entity level and could not be independently verified by the HKEX. The company was required to revise the performance condition to reference “consolidated revenue as reported in the issuer’s annual report under HKFRS,” which resulted in a 22% reduction in the number of options that vested in the first tranche, according to the company’s 2025 circular.

Practical Compliance Strategies for CFOs and Company Secretaries

Issuers planning post-IPO share option schemes should adopt three specific compliance measures to navigate the HKEX restrictions. First, the board should fix the grant date at a board meeting held immediately after the close of trading, using the same day’s closing price as the reference for the exercise price under Rule 17.03(4). This eliminates the five-day average complication, though the price must still be at least the higher of the two benchmarks. Second, for VIE-structure issuers, the performance conditions should be drafted to reference the listed entity’s consolidated financial statements under HKFRS or IFRS, with a reconciliation note to PRC GAAP included in the scheme document. Third, the scheme should include a mechanism for adjusting the exercise price in the event of a material market movement during the SAFE registration period, subject to independent shareholder approval under Rule 17.03(6) if the adjustment benefits a connected person.

The HKEX’s 2025 consultation paper on share schemes proposed additional restrictions on the maximum number of options that can be granted to any single grantee within a 12-month period, set at 1% of the issued share capital. While not yet enacted, this proposal signals a continued tightening of the regulatory environment. CFOs should factor this into their long-term equity planning, particularly for issuers with concentrated founder shareholdings where a single executive may have historically received a disproportionate share of option grants.

Closing Takeaways

1. HKEX Listing Rule 17.03(4) now prohibits granting options at a discount to the higher of the grant date closing price or the five-day average closing price, with retrospective effect from 1 January 2024.
2. VIE-structure issuers must synchronize the grant date with SAFE Circular 37 registration timelines to avoid pricing mismatches that require supplementary board approvals.
3. Performance conditions for post-IPO options must reference the listed entity’s consolidated financial statements under HKFRS or IFRS, not PRC GAAP alone.
4. The 2025 HKEX consultation paper proposes a 1% annual cap on options granted to any single grantee, which will require adjustments to concentrated equity plans.
5. Issuers should include a price adjustment mechanism in their scheme documents, subject to independent shareholder approval, to address market volatility during regulatory registration periods.